Camp4 Therapeutics Q2 Loss Per Share Misses Estimates On Non: cash derivative charge

CAMP4 Therapeutics

13/08/2026 21:22

Overview
US biopharmaceutical developer's Q2 loss per share missed analyst expectations
Net loss widened due to non-cash loss from derivative liability tied to private placement
Company closed $50.1 mln private placement tranche after quarter-end, extending cash runway through end-2028

Outlook
Company expects to initiate Phase 1/2 clinical trial of CMP-002 in Q4 2026
CAMP4 says current cash is sufficient to fund planned activities through end of 2028
Company has submitted regulatory filings in EU and UK to support broader trial enrollment

Result Drivers
DERIVATIVE LIABILITY IMPACT - Net loss increased mainly due to a $20.9 mln non-cash loss from change in fair value of derivative tranche liability tied to private placement
R&D SPENDING - Research and development expenses rose slightly, mainly due to clinical and preclinical study costs
G&A EXPENSES - General and administrative expenses increased, driven by higher stock-based compensation, partly offset by lower facilities costs

Company press release: ID:nGNX436CYW

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
Miss
$0.58
$0.21 (7 Analysts)
Q2 Operating Loss
 
$13.38 mln
 
Q2 Operating Expenses
 
$15.16 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for CAMP4 Therapeutics Corp is $8.00, about 76.6% above its August 12 closing price of $4.53

Reuters Recommended Reads
Aug 11 - Maze Therapeutics Q2 net loss widens, misses estimates on higher R&D expenses
Aug 13 - Abeona Therapeutics Q2 net loss widens, misses analyst expectations
Aug 12 - Eloxx Pharmaceuticals Q2 net loss widens on higher expenses

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)